The potentialities of oxytocin receptor inhibitors for endometriosis therapy

Maria I. Yarmolinskaya, Vladislav V. Khobets, Tatyana G. Tral, Natalia N. Tkachenko
Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology · 2020 · vol. 36(sup1) , pp. 16–19 · doi:10.1080/09513590.2020.1816722 · PMID:33305665 · W3112884370
article OA: hybrid CC0 ⤵ 3 in-corpus citations
📄 Open PDF View on OpenAlex View on PubMed View at publisher

Abstract

Objective Genital endometriosis (GE) is a widespread gynecological disease which requires its further pathogenesis investigation and search for new effective treatments. The known data of oxytocin receptor presence in endometrioid heterotopy smooth muscle cells give some grounds to assume oxytocin participation in the pathogenesis of endometriosis. The present study objective was to evaluate oxytocin level in peripheral blood (PB) in patients with endometriosis associated pain syndrome and to estimate the efficacy of oxytocin receptor inhibitors (IOXTR) administration based on animal endometriosis model.Materials and methods The basic group comprised 61 patients with endometriosis associated pain syndrome, while 21 patients formed the control group. VAS, MPQ, and BBS objective tests were applied for pain syndrome evaluation. Oxytocin level in PB was measured by immunoenzyme method. After confirmation of endometriosis experimental model formation in rats and further randomization, a daily IOXTR intra-abdominal injection was performed in a dose of 0.35 mg/kg/24 h in the basic group (n = 12) or saline solution administration in the control (n = 12). On the final stage, endometrioid heterotopy size measuring was performed along with histological examination.Results Oxytocin level in PB was authentically higher in patients with GE compared to the control: 51.45 (35.54–62.76) pg/mL and 27.64 (23.23–34.12) pg/mL, respectively (p<.001). Positive correlation between oxytocin PB level and pain syndrome expression was established in patients with GE: VAS (r = 0.76; p<.001), MPQ (r = 0.52; p<.001), and BBS (r = 0.57; p<.001). Based on the experimental disease model authentical decrease of endometrioid heterotopy average area was observed after IOXTR therapy compared to the control (7.3 ± 1.8 mm2 and 22.2 ± 1.2 mm2, respectively, p<.05).Conclusions The obtained results confirm the oxytocin role in the pathogenesis of endometrioid associated pain syndrome. The high efficacy of IOXTR administration based on animal model of surgically induced endometriosis allows viewing this method as a perspective therapy.

My notes (saved in your browser only)

Outcome instruments

VAS-pain

Condition tags

mesh:D004715mesh:D017699endometriosis

MeSH descriptors

Endometriosis Peritoneal Diseases Receptors, Oxytocin Vasotocin Adolescent Adult Animals Case-Control Studies Disease Models, Animal Drug Evaluation, Preclinical Endometriosis Endometriosis Endometriosis Endometriosis Female Humans Middle Aged Molecular Targeted Therapy Molecular Targeted Therapy Molecular Targeted Therapy

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (16)

Cited by (3)

SciLite annotations

organisms 2
rodents rattus sp.
chemicals 2
oxytocin oxytocin

Source provenance

europepmc
last seen: 2026-06-04T01:30:01.192114+00:00
openalex
last seen: 2026-06-04T00:00:01.174412+00:00
pubmed
last seen: 2026-05-13T22:21:30.380497+00:00
scilite
last seen: 2026-05-18T04:25:29.313245+00:00
License: CC0 · commercial use OK